PALISADE BIO INC

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

PALI$1.19+5.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
License revenue	$—	$—	$—	$250
Operating expenses:
Research and development	2,137	2,104	6,979	5,522
General and administrative	1,456	1,674	4,498	4,644
Total operating expenses	3,593	3,778	11,477	10,166
Loss from operations	(3,593)	(3,778)	(11,477)	(9,916)
Other (expense) income:
Interest expense	(6)	(8)	(9)	(11)
Other income, net	112	190	392	598
Total other income, net	106	182	383	587
Net loss	$(3,487)	$(3,596)	$(11,094)	$(9,329)
Net loss available to common stockholders	$(3,487)	$(3,612)	$(11,094)	$(9,345)
Basic and diluted weighted average shares used in computing basic and diluted net loss per common share*	1,500,409	489,624	1,168,277	402,074
Basic and diluted net loss per common share*	$(2.32)	$(7.38)	$(9.50)	$(23.24)

(*) Basic and diluted loss per common share and basic and diluted weighted average share used in computing basic and diluted loss per common share for thethree and nine months ended September 30, 2023 has been adjusted to reflect the 1-for-15 reverse stock split effected on April 5, 2024.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.